We offer several options to help cover the cost of XOLAIR® (omalizumab) for subcutaneous use for eligible patients who are uninsured, have been denied coverage by their health plans or are worried about drug co-pay costs.
The XOLAIR Co-pay Card Program might be able to help eligible patients with drug co-pay costs associated with their XOLAIR prescription.
If privately or publicly insured patients have difficulty paying for their XOLAIR co-pay, co-insurance or other expenses, XOLAIR Access Solutions can refer them to a co-pay assistance foundation* supporting their disease state.
GATCF was established to help patients with unmet medical needs who are uninsured or rendered uninsured by payer denial and who meet specific financial and medical criteria to receive XOLAIR free of charge.
| * | Genentech and Novartis Pharmaceuticals Corporation do not influence or control the operations of these co-pay assistance foundations, but XOLAIR Access Solutions can assist patients in navigating the process of seeking co-pay assistance by making an appropriate referral based on a patient’s diagnosis and by assisting with the application process. We cannot guarantee co-pay assistance once a patient has been referred by XOLAIR Access Solutions. The foundations to which we refer patients each have their own criteria for patient eligibility, including financial eligibility. |
FAQs
|
|
| Q: |
When should I refer my patient to XOLAIR Access Solutions for help?
|
| A: |
At any point after you have prescribed XOLAIR® (omalizumab), you can refer your patient to XOLAIR Access Solutions. Learn more in See How We Can Help.
|
|
Q: |
Can XOLAIR Access Solutions assist with co-pay issues?
|
| A: |
Yes. We may be able to help with co-pay issues in two ways, for both privately and publicly insured patients. Learn more in Find Patient Assistance.
|
XOLAIR®(omalizumab) for subcutaneous use IS INDICATED FOR adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.
XOLAIR has been shown to decrease the incidence of asthma exacerbations in these patients.
Important Limitations of Use
WARNING: Anaphylaxis Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, observe patients closely for an appropriate period of time after XOLAIR administration. Health care providers administering XOLAIR should be prepared to manage anaphylaxis that can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur (see Warnings and Precautions: Anaphylaxis).
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see full Prescribing Information, including Boxed WARNING and Medication Guide, for additional important safety information.